Death Despite COVID-19 Vaccine: Case Report

Year 2021, Volume: 3 Issue: 3, 142 - 144, 01.11.2021

Necip Gökhan Guner , Ensar Durmuş , Fatih Güneysu , Yusuf Yurumez , Nuray Aslan

https://doi.org/10.38175/phnx.936059

Abstract

n this study, a COVID-19 reverse transcription polymerase chain reaction (RT-PCR) positive case who died in the hospital with pneumonia after receiving two doses of inactive CoronaVac (Sinovac Life Sciences) vaccine is presented.
A 67-year-old female patient, who was vaccinated with two doses of the Coronovac vaccine, was admitted to the emergency room (ER) with dyspnea and cough. There was a bilateral ground glass image on thorax tomography. The patient’s RT-PCR test was positive, and he was admitted to the hospital’s V-19 ward. The patient, who stayed in the service for three days, was taken to the intensive care unit after his clinical condition deteriorated; moreover, she died after 11 days in the intensive care unit.
The expected protective effect may not be seen in old patients five days after two doses of vaccine. It would be appropriate for the vaccinated individuals to continue to protect themselves against COVID-19.

Keywords

Covid-19, vaccine, Coronovac, emergency department

COVID-19 Aşısına Rağmen Ölüm: Olgu Sunumu

Abstract

Bu çalışmada iki doz inaktif CoronaVac (Sinovac Life Sciences) aşısı olduktan sonra hastanede pnömoni nedeni ile hayatını kaybeden COVID-19 ters transkripsiyon polimeraz zincir reaksiyonu (RT-PCR) pozitif bir vaka sunulmuştur.
İki doz Koronovac aşısı yapılan 67 yaşında kadın hasta, nefes darlığı ve öksürük şikayeti ile acil servise (AS) başvurdu. Toraks tomografisinde bilateral buzlu cam görüntüsü mevcuttu. Hastanın RT-PCR testi pozitif çıktı ve hastanenin COVID-19 servisine kaldırıldı. Üç gün serviste kalan hasta, klinik durumunun ağırlaşması üzerine yoğun bakıma alındı; ayrıca yoğun bakım ünitesinde 11 gün kaldıktan sonra öldü.
İki doz aşıdan beş gün sonra, yaşlı hastalarda beklenen koruyucu etki görülmeyebilir. Aşılanan bireylerin kendilerini COVID-19’a karşı korumaya devam etmeleri uygun olacaktır.

Keywords

covid-19, aşı, coronovac, acil servis

References

• WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2021 Jan 26]. Available from: https://covid19.who.int
• Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26–35.
• CDC. Different COVID-19 Vaccines [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2021 May 5]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html
• [COVID-19 Vaccine National Implementation Strategy] COVID-19 Aşısı Ulusal Uygulama Stratejisi [İnternet]. [T.R. Ministry of Health Covid-19 Vaccine Information Platform]T.C. Sağlık Bakanlığı Covid-19 Aşısı Bilgilendirme Platformu. 2021 [cited 2021 Apr 30]. Available from: https://covid19asi.saglik.gov.tr/TR-77706/covid-19-asisi-ulusal-uygulama-stratejisi.html
• Yang L, Jin J, Luo W, Gan Y, Chen B, Li W. Risk factors for predicting mortality of COVID-19 patients: A systematic review and meta-analysis. PloS One. 2020;15(11):e0243124.
• Guneysu F, Guner NG, Erdem AF, Durmus E, Durgun Y, Yurumez Y. Can COVID-19 mortality be predicted in the emergency room? J Coll Physicians Surg Pak. 2020;31(09):928–932.
• Keehner J, Horton LE, Pfeffer MA, Longhurst CA, Schooley RT, Currier JS, et al. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. N Engl J Med. 2021;384:1774-1775.
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615.
• Mallapaty S. China COVID vaccine reports mixed results — what does that mean for the pandemic? Nature [Internet]. Nature. 2021 Jan 15. doi: 10.1038/d41586-021-00094-z. Epub ahead of print. Available from: https://www.nature.com/articles/d41586-021-00094-z